Clinical trial
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB…
NCT00405301 · All India Institute of Medical Sciences, Other · Completed
Key facts
| NCT number | NCT00405301 |
|---|---|
| Title | Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage |
| Official title | Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity |
| Lead sponsor | All India Institute of Medical Sciences, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Drug Induced Hepatotoxicity, Tuberculosis |
| Intervention type | Drug |
| Interventions | Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day) |
| Enrollment | 175 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Nov 30, 2006 |
| Last update posted | Feb 16, 2012 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: